Monday, 17 March 2025
  
Login

Australia's most trusted
source of pharma news

Monday, 17 March 2025
News

Gilead leapfrogs to Phase 3 trial

Posted 12 March 2025 PM

Gilead has garnered such strong results from Phase 1 trials of two new formulations of a pre-exposure prophylaxis (PrEP) antiviral targeting HIV, that it will leap straight to Phase 3 trials this year.

The Phase 1 trial was for two formulations of a once-yearly intramuscular injection of lenacapavir. Gilead said the injections "achieved and maintained plasma concentrations exceeding those associated with HIV prevention efficacy".

To see the whole article, please login

Popular

Worst off-label offenders targeted
Senior leader lands former job
Where HCPs are feeling fresh pain
Blockbusters join TGA's review list
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (31)

Clinical & Medical, R&D (13)

Regulatory, Pharmacovigilance & QA (1)

Other (18)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home